Grace Halsey

March 13, 2025

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

March 13, 2025

Elinzanetant, a first in class dual neurokinin-1 and 3 (NK-1,3) receptor antagonist in late-stage clinical development, has a US PDUFA date set for July 26, 2025.

March 12, 2025

Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.

March 12, 2025

Brian S Kim, MD, a leading investigator in the study of itch physiology, discusses the marked progress made in understanding the sensation and targeting its treatment.

March 12, 2025

The impact of childhood onset AD on adult psychosocial experience is far reaching and profound according to findings from the Scars of Life Survey.

March 12, 2025

The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.

March 11, 2025

The menopausal symptom and lifestyle management app provides guideline-based CBT principles to augment hormone therapy or even to replace it for some women.

March 11, 2025

CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.

March 10, 2025

AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.

March 10, 2025

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.